Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.

Xiang M, Colevas AD, Holsinger FC, Le QX, Beadle BM.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1065-1073. doi: 10.6004/jnccn.2019.7297.

PMID:
31487677
2.

Fluorescence molecular imaging for identification of high-grade dysplasia in patients with head and neck cancer.

Fakurnejad S, van Keulen S, Nishio N, Engelen M, van den Berg NS, Lu G, Birkeland A, Baik F, Colevas AD, Rosenthal EL, Martin BA.

Oral Oncol. 2019 Aug 12;97:50-55. doi: 10.1016/j.oraloncology.2019.08.008. [Epub ahead of print]

3.

Development and validation of radiomic signatures of head and neck squamous cell carcinoma molecular features and subtypes.

Huang C, Cintra M, Brennan K, Zhou M, Colevas AD, Fischbein N, Zhu S, Gevaert O.

EBioMedicine. 2019 Jul;45:70-80. doi: 10.1016/j.ebiom.2019.06.034. Epub 2019 Jun 27.

4.

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL.

Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.

5.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.

Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.

PMID:
31239321
6.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129689. Epub 2019 Jun 3. No abstract available.

7.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R.

J Clin Invest. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129688. Epub 2019 Jun 3. No abstract available.

8.

The Sentinel Margin: Intraoperative Ex Vivo Specimen Mapping Using Relative Fluorescence Intensity.

van Keulen S, Nishio N, Birkeland A, Fakurnejad S, Martin B, Forouzanfar T, Cunanan K, Colevas AD, S van den Berg N, Rosenthal E.

Clin Cancer Res. 2019 Aug 1;25(15):4656-4662. doi: 10.1158/1078-0432.CCR-19-0319. Epub 2019 May 29.

PMID:
31142505
9.

Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.

Nishio N, van den Berg NS, van Keulen S, Martin BA, Fakurnejad S, Zhou Q, Lu G, Chirita SU, Kaplan MJ, Divi V, Colevas AD, Rosenthal EL.

Mol Imaging Biol. 2019 May 3. doi: 10.1007/s11307-019-01358-x. [Epub ahead of print]

PMID:
31054001
10.

Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.

Le QT, Colevas AD, O'Sullivan B, Lee AWM, Lee N, Ma B, Siu LL, Waldron J, Lim CM, Riaz N, Lynn J, Malik S.

J Natl Cancer Inst. 2019 Mar 26. pii: djz044. doi: 10.1093/jnci/djz044. [Epub ahead of print]

PMID:
30912808
11.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK.

J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27.

PMID:
30811285
12.

The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer.

van Keulen S, Nishio N, Fakurnejad S, Birkeland A, Martin BA, Lu G, Zhou Q, Chirita SU, Forouzanfar T, Colevas AD, van den Berg NS, Rosenthal EL.

J Nucl Med. 2019 Jun;60(6):758-763. doi: 10.2967/jnumed.118.222810. Epub 2019 Feb 7.

13.

Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma.

van Keulen S, van den Berg NS, Nishio N, Birkeland A, Zhou Q, Lu G, Wang HW, Middendorf L, Forouzanfar T, Martin BA, Colevas AD, Rosenthal EL.

Oral Oncol. 2019 Jan;88:58-65. doi: 10.1016/j.oraloncology.2018.11.012. Epub 2018 Nov 21.

PMID:
30616798
14.

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT.

Lancet. 2019 Jan 5;393(10166):40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15.

PMID:
30449625
15.

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.

Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK, Le QT, Lee N, Colevas AD, Seiwert T, Hayes DN, Riaz N, Vermorken JB, O'Sullivan B, He QM, Yang XJ, Tang LL, Mao YP, Sun Y, Liu N, Ma J.

Ann Oncol. 2019 Jan 1;30(1):68-75. doi: 10.1093/annonc/mdy470.

PMID:
30407504
16.

Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.

Xiang M, Holsinger FC, Colevas AD, Chen MM, Le QT, Beadle BM.

Cancer. 2018 Dec 1;124(23):4486-4494. doi: 10.1002/cncr.31708. Epub 2018 Oct 17.

PMID:
30332498
17.

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial.

Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, Sarkar I, Molinero L, Grossman W, Kabbinavar F, Fassò M, O'Hear C, Powderly J.

Ann Oncol. 2018 Nov 1;29(11):2247-2253. doi: 10.1093/annonc/mdy411.

PMID:
30219915
18.

Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study.

Chang ALS, Tran DC, Cannon JGD, Li S, Jeng M, Patel R, Van der Bokke L, Pague A, Brotherton R, Rieger KE, Satpathy AT, Yost KE, Reddy S, Sarin K, Colevas AD.

J Am Acad Dermatol. 2019 Feb;80(2):564-566. doi: 10.1016/j.jaad.2018.08.017. Epub 2018 Aug 24. No abstract available.

19.

Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.

Chen MM, Colevas AD, Megwalu U, Divi V.

Oral Oncol. 2018 Sep;84:71-75. doi: 10.1016/j.oraloncology.2018.07.012. Epub 2018 Jul 21.

PMID:
30115479
20.

PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.

Amoils M, Kim J, Lee C, Sunwoo JB, Colevas AD, Aasi SZ, Hollmig ST, Ma Y, Divi V.

Otolaryngol Head Neck Surg. 2019 Jan;160(1):93-99. doi: 10.1177/0194599818788057. Epub 2018 Jul 17.

PMID:
30012051
21.

Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence.

Gao RW, Teraphongphom NT, van den Berg NS, Martin BA, Oberhelman NJ, Divi V, Kaplan MJ, Hong SS, Lu G, Ertsey R, Tummers WSFJ, Gomez AJ, Holsinger FC, Kong CS, Colevas AD, Warram JM, Rosenthal EL.

Cancer Res. 2018 Sep 1;78(17):5144-5154. doi: 10.1158/0008-5472.CAN-18-0878. Epub 2018 Jul 2.

22.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

23.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

24.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

25.

Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.

Gao RW, Teraphongphom N, de Boer E, van den Berg NS, Divi V, Kaplan MJ, Oberhelman NJ, Hong SS, Capes E, Colevas AD, Warram JM, Rosenthal EL.

Theranostics. 2018 Mar 28;8(9):2488-2495. doi: 10.7150/thno.24487. eCollection 2018.

26.

A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

Gubens MA, Chuang JC, Akerley W, Langer CJ, Clément-Duchêne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA.

J Thorac Dis. 2018 Jan;10(1):219-227. doi: 10.21037/jtd.2017.12.30.

27.

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.

Trieu V, Pinto H, Riess JW, Lira R, Luciano R, Coty J, Boothroyd D, Colevas AD.

Oncologist. 2018 Jul;23(7):764-e86. doi: 10.1634/theoncologist.2017-0618. Epub 2018 Mar 14.

29.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J.

Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

30.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

31.

Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME.

JAMA Dermatol. 2017 Jul 1;153(7):694-697. doi: 10.1001/jamadermatol.2017.0989.

32.

Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.

Amoils M, Lee CS, Sunwoo J, Aasi SZ, Hara W, Kim J, Sirjani D, Colevas AD, Chang AL, Divi V.

Head Neck. 2017 May;39(5):881-885. doi: 10.1002/hed.24692. Epub 2017 Mar 2.

PMID:
28252823
33.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B.

J Clin Oncol. 2017 Feb 10;35(5):490-497. doi: 10.1200/JCO.2016.68.3300. Epub 2016 Dec 28.

34.

Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.

Makkouk A, Sundaram V, Chester C, Chang S, Colevas AD, Sunwoo JB, Maecker H, Desai M, Kohrt HE.

Ann Oncol. 2017 Feb 1;28(2):415-420. doi: 10.1093/annonc/mdw570.

35.

Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.

Tran DC, Colevas AD, Chang AL.

JAMA Dermatol. 2017 Jan 1;153(1):92-94. doi: 10.1001/jamadermatol.2016.3884. No abstract available.

PMID:
27784038
36.

Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.

Pan JJ, Ng WT, Zong JF, Lee SW, Choi HC, Chan LL, Lin SJ, Guo QJ, Sze HC, Chen YB, Xiao YP, Kan WK, O'Sullivan B, Xu W, Le QT, Glastonbury CM, Colevas AD, Weber RS, Lydiatt W, Shah JP, Lee AW.

Cancer. 2016 Nov 15;122(21):3307-3315. doi: 10.1002/cncr.30198. Epub 2016 Jul 19.

37.

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML.

N Engl J Med. 2016 Nov 10;375(19):1856-1867. Epub 2016 Oct 8.

38.

BRAF inhibitor therapy of primary ameloblastoma.

Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Oct;122(4):518-9. doi: 10.1016/j.oooo.2016.05.017. Epub 2016 Jul 5. No abstract available.

PMID:
27651290
39.

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.

Rosen LS, LoRusso P, Ma WW, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI.

Invest New Drugs. 2016 Oct;34(5):604-13. doi: 10.1007/s10637-016-0374-3. Epub 2016 Jul 16.

PMID:
27424159
40.

Design and rationale of a prospective, multi-institutional registry for patients with sinonasal malignancy.

Beswick DM, Holsinger FC, Kaplan MJ, Fischbein NJ, Hara W, Colevas AD, Le QT, Berry GJ, Hwang PH.

Laryngoscope. 2016 Sep;126(9):1977-80. doi: 10.1002/lary.25996. Epub 2016 Jun 10.

PMID:
27283472
41.

BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.

Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jul;122(1):e5-7. doi: 10.1016/j.oooo.2015.12.016. Epub 2016 Feb 23.

PMID:
27209484
42.

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Narayanan S, Colevas AD.

Curr Treat Options Oncol. 2016 Jun;17(6):30. doi: 10.1007/s11864-016-0404-6. Review.

PMID:
27139457
43.

Number of positive nodes is superior to the lymph node ratio and American Joint Committee on Cancer N staging for the prognosis of surgically treated head and neck squamous cell carcinomas.

Roberts TJ, Colevas AD, Hara W, Holsinger FC, Oakley-Girvan I, Divi V.

Cancer. 2016 May 1;122(9):1388-97. doi: 10.1002/cncr.29932. Epub 2016 Mar 11.

44.

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.

Iberri DJ, Colevas AD.

Oncologist. 2016 Mar;21(3):391. doi: 10.1634/theoncologist.2015-0177erratum. No abstract available.

45.

Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.

Ally MS, Ransohoff K, Sarin K, Atwood SX, Rezaee M, Bailey-Healy I, Kim J, Beachy PA, Chang AL, Oro A, Tang JY, Colevas AD.

JAMA Dermatol. 2016 Apr;152(4):452-6. doi: 10.1001/jamadermatol.2015.5473.

46.

Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review.

Zhu GA, Lira R, Colevas AD.

Oral Oncol. 2016 Feb;53:36-41. doi: 10.1016/j.oraloncology.2015.11.018. Epub 2015 Dec 9.

PMID:
26684543
47.

Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.

Pan JJ, Ng WT, Zong JF, Chan LL, O'Sullivan B, Lin SJ, Sze HC, Chen YB, Choi HC, Guo QJ, Kan WK, Xiao YP, Wei X, Le QT, Glastonbury CM, Colevas AD, Weber RS, Shah JP, Lee AW.

Cancer. 2016 Feb 15;122(4):546-58. doi: 10.1002/cncr.29795. Epub 2015 Nov 20.

48.

New Diseases and New Treatments--Head and Neck Cancer Updates.

Colevas AD.

Hematol Oncol Clin North Am. 2015 Dec;29(6):xiii-xiv. doi: 10.1016/j.hoc.2015.08.004. Epub 2015 Sep 15. No abstract available.

PMID:
26568555
49.

NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.

Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM.

J Natl Compr Canc Netw. 2015 Nov;13(11):1337-46.

PMID:
26553764
50.

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.

Iberri DJ, Colevas AD.

Oncologist. 2015 Dec;20(12):1393-403. doi: 10.1634/theoncologist.2015-0177. Epub 2015 Oct 7. Review. Erratum in: Oncologist. 2016 Mar;21(3):391.

Supplemental Content

Loading ...
Support Center